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We show the cowpox genome (Brighton Red strain) contains a single copy gene, crmC, expressed at late times during
viral infection, encoding a soluble, secreted protein whose sequence marks it as a new member of the TNF receptor family.
The cysteine-rich protein contains 186 amino acids, the N-terminal 21 of which constitute a signal peptide, and two potential
N-linked glycosylation sites. The 25-kDa recombinant protein binds TNF specifically and completely inhibits TNF-mediated
cytolysis. The strongest sequence homologues are the ligand-binding regions of the type II cellular TNF receptor (TNFRII)
and CrmB, a distinct pox virus gene also encoding a soluble TNF binding protein. Unlike TNFRII and CrmB, CrmC does not
bind lymphotoxin (LTa, TNFb) and lacks the conserved (but nonhomologous) 150-residue C-terminal domain of CrmB
proteins. The presumed function of CrmC is viral inhibition of host-elicited TNF. q 1996 Academic Press, Inc.
INTRODUCTION from the subsequent construction of a recombinant myx-
oma poxvirus (MV), also a leporipoxvirus and very similar
All viruses which productively infect eukaryotes must
to SFV, inactivated at both T2 loci. Whereas wild-type MV
possess mechanisms to evade host immune responses
is uniformly fatal to its host, the T2 deletion mutant shows
that would otherwise lead rapidly to their elimination
nearly two-thirds survivability (Upton et al., 1991). Cow-
(Smith et al., 1990, 1991; reviewed by Marrack and Kap-
pox virus (CPV), an orthopoxvirus, also contains diploid
pler, 1994; Smith and Goodwin, 1994). Notwithstanding
copies of an extremely homologous gene (termed crmB),
the diversity of eukaryotic viruses, one common mecha-
ITR localized, and expressed early after infection (Hu et
nism is the disruption of cytokine networks crucial to the
al., 1994). The TNF/LTa binding properties of CrmB are
amplification of inflammatory and antigen-specific re-
virtually identical to those of SFV T2. Thus, T2 (CrmB)
sponses (Pickup, 1994). Tumor necrosis factors (TNF and
remains a classic example of a viral gene which repre-
lymphotoxin or LTa) and interleukin 1 (IL1a, b) as unusu-
sents an acquired cellular gene, altered, and subverted
ally prominent and pleiotropic cytokines produced early
to viral advantage (Smith et al., 1990; Smith and Goodwin,
in the immune response, are often key targets. The first
1995). The later demonstrations of other poxvirus genes
identification of such a viral immunomodifier clearly cel-
encoding soluble cytokine receptors for IL1 and several
lular in origin was the T2 gene in Shope Fibroma virus interferons clearly establish this phenomena as a gen-
(SFV), a leporipoxvirus which causes malignant tumors eral mode of immune suppression (Alcamı´ and Smith,
in neonatal and immunocompromised rabbits (Smith et 1992; Spriggs et al., 1992; Upton et al., 1992; Symons et
al., 1990). T2, a diploid gene located in the inverted termi- al., 1995).
nal repeats (ITRs), was shown to encode a 58-kDa solu- A quite different mechanism of abrogating the effects
ble, secreted protein that represents an acquired form of host-elicited cytokines is provided by the CPV crmA
of the type II cellular TNF receptor (TNFRII, p75). Like (cytokine response modifier A) gene (Ray et al., 1992).
TNFRII, T2 binds both TNF and LTa, shows cross-compe- crmA encodes a 38-kDa cytoplasmic protein shown to
tition for ligand binding, and completely inhibits TNF- or inhibit activation (by proteolytic cleavage) of the pro-form
LTa-mediated cellular cytotoxicity in vitro (Smith et al., of IL1b, achieved through inactivation of the IL1b con-
1991). One function of such a viral ‘‘soluble receptor’’ is verting enzyme (ICE). CrmA has also been shown to in-
presumably to bind host-elicited TNF and LTa, pre- hibit apoptosis induced by either TNF or the Fas ligand
venting activation of cellular TNF receptors and concomi- (a member of the TNF family) and to inhibit at least one
tant antiviral effects. Support for this argument comes member of the ICE family of cysteine proteases believed
to mediate this phenomena (Miura et al., 1993; Tewari
et al., 1995; Los et al., 1995; Talley et al., 1995).1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (206) 233-9733. E-mail: Smithc@immunex.com. Several factors stimulated us to search for additional
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TNF inhibitors in the Cowpox genome. First, the early Sequence analysis
and pivotal roles TNF plays in any immune response
The 1.35-kb PstI–ClaI fragment of the PstI J fragmentmight indicate the need for additional viral genes to effect
of CPV-BR (Pickup et al., 1984), containing the entireadequate suppression. Adenovirus, for example, with a
crmC gene, was inserted into the NsiI–ClaI site ofdouble-stranded DNA genome (36 kb) only one-sixth the
pGEM7zf(/) as plasmid p1464. The nucleotide se-size of CPV, nevertheless devotes at least five proteins to
quences of both strands of the insert were determinedthe modulation of host-elicited TNF, by as yet imperfectly
by standard methods.understood mechanisms (Wold et al., 1995). Second, sev-
DNA and protein sequences were analyzed with theeral open reading frames (ORFs) subsequently have
aid of software from the Genetics Computer Groupbeen identified in the course of general sequencing of
(1991).poxvirus genomes which show homology to TNF recep-
tor family members. The C22L ORF (duplicated as B8 in RNA analyses
the right ITR) in the Copenhagen strain of vaccinia virus
can be arranged tandemly with downstream ORFs RNAs were extracted from cells according to the
method of Chomczynski and Sacchi (1987). Virus-infectedthrough frameshifts and stop codon overrides to com-
plete a (disrupted) ORF with homology to the N-terminal human 143 cells (2 1 107) were washed with phosphate-
buffered saline (PBS) and lysed by the addition of 2 mlhalf of T2 (CrmB) and the extracellular regions of both
type I and type II cellular TNF receptors (Goebel et al., of 4 M guanidium thiocyanate, 0.025 M NaOAC (pH 7.0),
0.5% sarkosyl, and 0.72% b-mercaptoethanol. The lysate1990; Upton et al., 1991). Such an ORF, clearly nonfunc-
tional, necessarily shows homology to all other TNF re- was passed through a 22.5-gauge needle five times, after
which 0.2 ml of 2 M NaOAC, pH 4.0, was added beforeceptor family members as well (Smith and Goodwin,
1994). Two other ORFs with homology to the TNF recep- phenol-chloroform extraction. The RNAs were precipi-
tated and then resuspended in diethyl pyrocarbonatetor family are termed A53R (vaccinia Copenhagen) and
Sal 19R (vaccinia WR). Both are parts of disrupted genes, (DEPC)-treated water. Residual DNA was removed by
treatment with RQ1 DNase (Promega Corp., Madison,also requiring frameshifts and stop codon overrides to
assemble a longer ORF (Upton et al., 1991; Howard et WI). The RNA was then deproteinized, precipitated, and
resuspended in DEPC-treated water as described above.al., 1991). Sal19R has been suggested to be the WR
equivalent of T2 (Howard et al., 1991). Neither of these Polyadenylated RNAs were recovered by oligo(dT) cellu-
lose chromatography (Aviv and Leder, 1972).two ORFs are located in the ITRs. Third, genetic analysis
of the cowpox genome, which assesses altered pock Primer extension analysis, as described (Sambrook
et al., 1989), was used to characterize the 5*-ends ofmorphology in a chick chorioantoic membrane assay,
suggests more than one loci can be responsible for the transcripts of the crmC gene. Oligonucleotide primers
A53R1, 5*-ATAGTACATACAGTCAGC-3*, complementarychange from normal red pocks to white pocks. crmA, for
example, was originally identified in this manner. Inacti- to the region between nucleotides 374 and 391 (Fig. 2)
of the gene, were 5* end-labeled with 32P by the methodvation of both crmB loci, however, does not result in such
phenotypic changes. Another TNF inhibitor is therefore of Weaver and Weissman (1979). The labeled primers
were annealed (overnight at 377) to 100 mg of unfraction-a reasonable candidate.
Here we describe the identification and expression of ated RNAs from virus-infected cells. Primer:RNA hybrids
were precipitated on ice with 2 vol of ethanol for 1 hr,a cowpox gene, crmC, distinct from crmB, which encodes
a second soluble, secreted TNF receptor. Although one after which they were dissolved in 20 ml reverse tran-
scriptase buffer (50 mM Tris–HCl, pH 7.6, 60 mM KCl,function of this protein (CrmC) is, like CrmB, no doubt
inhibition of TNF, differences in temporal expression, li- 10 mM MgCl2 , 1 mM of each dNTP, 1 mM dithiothreitol,
1 unit/ml RNasin, 50 mg/ml actinomycin D). Annealedgand binding properties, and structural features raise
interesting questions about mechanisms. primers were extended (for 2 hr at 377) by the addition
of 28 units AMV reverse transcriptase (USB, Cleveland,
OH). RNAs were then removed by digestion with 2 mg/MATERIALS AND METHODS
ml RNaseA (Boehringer Mannheim Biochemicals, India-
Cells and viruses
napolis, IN) at 377 for 30 min. Proteins were removed
by phenol-chloroform extraction. The DNA was ethanol-The Brighton Red strain of cowpox virus (CPV-BR) and
the Western Reserve strain of vaccinia virus (VV-WR) precipitated and then resuspended in formamide loading
buffer (80% formamide, 10 mM EDTA, pH 8.0, 0.025%were grown in human osteosarcoma 143 cells cultured
as monolayers in minimal essential medium (MEME from xylene cyanol FF, and 0.025% bromophenol blue). The
32P-labeled extension products were electrophoresed inGibco Laboratories, Grand Island, NY) supplemented
with 5% fetal calf serum. Viruses were also cultured in a 6% polyacrylamide gel containing 8 M urea and visual-
ized by autoradiography of the dried gel.the chorioallantoic membranes of chick embryos as de-
scribed (Pickup et al., 1984). S1 nuclease protection analysis was used to deter-
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mine the extent of complementarity between the crmC p1559, which was used for the inactivation of crmC gene,
was constructed by replacing most of the coding regiongene and the 5*-ends of its mRNAs (Sambrook et al.,
1989). The polymerase chain reaction (PCR) was used to of the crmC gene (between nucleotides 460 and 958
shown in Fig. 2) with the Escherichia coli lacZ gene undergenerate the hybridization probe. Oligonucleotide primer
A53R1 5*-ATAGTACATACAGTCAGC-3*, complementary the control of a vaccinia virus promoter. The latter gene
was obtained as the 3.4-kb PstI–SmaI fragment of pSC11to the region between nucleotides 374 and 391 (Fig. 2),
was labeled at its 5* end with 32P by the method of (Chakrabarti et al., 1985), which was kindly provided by
Dr. B. Moss (NIH). This fragment was ligated to a 3.85-Weaver and Weissman (1979). Then 20 pmol of this 5*-
end labeled primer and 20 pmol of the SP6 universal kb PCR product generated with primers A53R2 and
A53R3 on template DNA of plasmid p1464. The A53R2promoter primer, 5*-GATTTAGGTGACACTATAG-3* (Pro-
mega Corp., Madison, WI), were used to amplify a DNA primer comprises the sequence 5*-GCCGATATCAGT-
ACATACAGTCAGC-3*, including an EcoRV cleavage sitefragment of 400 bp (nucleotides 1–391 in Fig. 2) from
the DNA of plasmid p1464, with nucleotide 391 labeled and the sequence complementary to nucleotides 374–
389 in Fig. 2. The A53R3 primer comprises the sequencewith 32P. The radiolabeled PCR product of 400 bp was
purified from gel for use as the probe in the S1 nuclease 5*-CGCGCTGCAGCCTCCATGCAAACTATC-3*, including
a PstI cleavage site and the sequence corresponding toprotection analysis. RNA (120 mg) extracted from cells
16 hr after infection with cowpox virus were precipitated nucleotides 888–904 in Fig. 2. In order to generate plas-
mid p1559, the 3.85-kb PCR products, which containedwith radiolabeled probe (1 1 105 cpm) and resuspended
in 30 ml hybridization buffer (40 mM PIPES, pH 6.4, 1 mm the pGEM7zf(/) vector and the two ends of the crmC
gene (from plasmid p1464), were first digested withEDTA, pH 8.0, 0.4 M NaCl, 80% formamide). The nucleic
acids were denatured at 857 for 10 min, and then allowed EcoRV and PstI and then ligated with the 3.4-kb PstI–
SmaI fragments of pSC11 DNA containing the lacZ gene.to cool gradually to 217, allowing annealing for 5 hr. Re-
sidual single-stranded nucleic acids were digested with Human 143 cells (2 1 106) were infected with cowpox
virus (0.1 plaque-forming units per cell). Five hours after200 units of S1 nuclease (Pharmacia, Piscataway, NJ) in
300 ml S1 digestion buffer (0.28 M NaCl, 0.05 M sodium infection the cells were transfected with 15 mg of p1559
DNA, using 50 mg of lipofectin reagent (Gibco-BRL, Gaith-acetate (pH 4.5), 4.5 mM ZnSO4) at 217 for 1 hr. The
protected labeled products were resolved by electropho- ersburg, MD). The total virus progeny were harvested 48
hr after infection. Virus progeny containing the lacZ generesis in a 6% polyacrylamide gel containing 8 M urea,
and visualized by autoradiography of the dried gel. were isolated from blue plaques formed in human 143
cells cultured under agar overlays containing X-gal (300
mg/ml). DNA hybridization analysis (Southern, 1975) wasConstruction of recombinant viruses
used to confirm that cowpox virus A512 contained the
inserted lacZ gene in the place of the crmC gene, withoutA recombinant vaccinia virus (A555) containing the cow-
pox virus crmC gene was constructed according to the duplication of the intact crmC gene. Such duplication
might occur through a single crossover event betweenmethod of Mackett et al. (1982, 1984), using plasmid p1695
to insert the crmC gene into the thymidine kinase gene the genome and the circular insertion vector.
A cowpox virus (A513) containing inactivated crmC andof the vaccinia virus, as follows. Plasmid p1695 was con-
structed by inserting the 2.1-kb EcoRI–ClaI fragment from crmB genes was obtained from recombinants between
cowpox virus A512, which lacks the crmC gene, andthe PstI J fragment of CPV-BR, containing the entire crmC
gene, into the EcoRI and ClaI sites of p1696. Plasmid cowpox virus A500, which lacks both copies of the crmB
gene (Hu et al., 1994). Human 143 cells were coinfectedp1696 was constructed by inserting the 1.8-kb HindIII–
XhoI fragment containing the thymidine kinase gene of with A512 and A500 virus (each at 5 plaque-forming units
per cell). Progeny virus were harvested 2 days after infec-vaccinia virus into the HindIII and XhoI sites of
pGEM7zf(/). Human 143 cells were infected with vaccinia tion. Recombinant viruses lacking the crmB and crmC
genes were isolated by selection for viruses that ex-virus (0.1 plaque-forming units per cell). One hour after
infection the cells were transfected with 15 mg of p1695 pressed both genes used to replace the crmB and crmC
genes, namely the E. coli guanosine phosphoribosyl-DNA, using 50 mg of lipofectin reagent (Gibco-BRL, Gaith-
ersburg, MD). The total virus progeny were harvested 48 transferasese (gpt) gene and the lacZ gene. These
DcrmB, DcrmC cowpox viruses were isolated from bluehr after infection. The thymidine kinase negative progeny
were selected in cells grown in the presence of 25 mg/ml plaques formed in human 143 cells cultured in media
containing 12 mg/ml mycophenolic acid, 250 mg/ml xan-5-bromodeoxyuridine. The presence of the crmC gene in
the genome of vaccinia virus A555 was confirmed by DNA thine, and 15 mg/ml hypoxanthine, as described by Falk-
ner and Moss (1988), and overlaid with agar containinghybridization analysis (Sambrook et al., 1989).
A recombinant cowpox virus (A512) containing an inac- 300 mg/ml X-gal. DNA hybridization analysis was used
to confirm that cowpox virus A513 lacked intact copiestivated crmC gene was constructed according to the
method of Chakrabarti et al. (1985) as follows. Plasmid of the crmB and crmC genes.
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Construction and expression of recombinant CrmC gel, using a discontinuous buffer system (Laemmli, 1970).
Radiolabeled proteins were visualized by autoradiogra-fusion protein
phy of the dried gel. Radiolabeled marker proteins (14C-
A soluble form of the CrmC protein, expressed as a labeled) that served as molecular mass standards were
human IgG1 Fc fusion chimera, was constructed in the obtained from Amersham (Arlington Heights, IL).
mammalian expression vector pDC406 (McMahan et al.,
1991) as described (Mohler et al., 1993). Briefly, oligonu- Recombinant proteins
cleotides were first synthesized to allow amplification of
Human TNF was expressed in yeast with an octapep-the entire CrmC ORF from the viral genome: 5*-ATAGCG-
tide epitope tag at the N-terminus and purified by affinityGCCGCCACCATGGATATAAAGAATTTGCTGACT-3* (up-
chromatography with a monoclonal antibody (M2) spe-stream), and 5*-CGCAGATCTGGGCTCATTACATTTAGA-
cific for the epitope (Hopp et al., 1988). Human IL1a andTAGTTTGCATGG-3* (downstream). The first primer intro-
b, human IL2, human IL4, human IL7, human IL15, humanduces a NotI site upstream of the initiator methionine of
granulocyte-macrophage colony stimulating factor (GM-the CrmC ORF, and the downstream primer inserts the
CSF), and human granulocyte-colony stimulating factoramino acids Glu and Pro, the first two amino acids of
were expressed and purified at Immunex from clonedthe IgG1 hinge region, just after the viral ORF C-terminus.
cDNAs and assayed for full biological activity in standardThis primer also contains a BglII site used to fuse the
assays. Human LTa, human IL6, human IL8, murine TNF,CrmC protein to the remainder of the Fc coding region.
and human transforming growth factor bwere purchasedThe resulting PCR product was digested with NotI and
commercially (R & D Systems, Minneapolis, MN). HumanBglII, and this fragment was ligated to a BglII/NotI frag-
g-interferon was obtained from Genzyme (Boston, MA),ment encoding the human IgG1 Fc region. The resulting
and murine nerve growth factor was from Bioproductsfusion gene was cloned into the expression vector
(Indianapolis, IN).pDC406 at the NotI site.
A chimeric surface form of murine LTa (muLTa) wasFor expression of the CrmC/Fc fusion protein, plasmid
constructed by fusing the intracellular, transmembrane,was transfected into CV-1/EBNA cells (ATCC CRL 10478)
and (transmembrane-proximal) extracellular linker regionas previously described (McMahan et al., 1991). Super-
of human pro-TNF with the mature form of murine LTa.natant from the transfected cells was harvested weekly
The chimera is thus a type II membrane protein, whosefor up to 4 weeks, and the Ig fusion protein purified by
C-terminal (extracellular) element is mature murine LTa.affinity chromatography on protein G Sepharose (Phar-
The construction of the vector expressing the chimericmacia, Upsula, Sweden). A similar construct of the extra-
huTNF/muLTa utilized PCR to amplify the N-terminal 79cellular region of human TNFRII (huTNFRII/Fc) was made
amino acids of huTNF with incorporated SalI and BglIIand purified for control experiments (Mohler et al., 1993).
sites at the 5* and 3* ends, respectively. Likewise, the
Metabolic labeling studies of CPV-infected cells C-terminal portion of muLTa (amino acids 50–202) was
PCR amplified, with incorporated BglII and NotI sites at
Human 143 cells in subconfluent monolayers in 25-
the 5* and 3* ends, respectively. Subsequently, fragments
cm2 flasks were infected with viruses at multiplicities of
were ligated into the pDC406 expression vector. The re-
10 plaque forming units per cell. After 1 hr adsorption at
sulting chimera (surmuLTa) contains two additional amino
377, 8 ml MEME plus 5% serum were added to each
acids (Arg and Ser), located between at the huTNF/
culture. The medium was removed 11 hr later and the
muLTa interface resulting from the introduction of the
cells were washed twice with phosphate-buffered saline,
BglII site. Expression of surmuLTa in mammalian cells
after which 2 ml of cysteine-free MEME (Gibco Labora-
was demonstrated by surface-radioiodinating trans-
tories, Grand Island, NY) without serum, but supple-
fected CV1/EBNA cells and specifically immunoprecipi-
mented with 100 mCi [35S]cysteine at 1300 Ci/mmol (Am-
tating a 28 kDa band with TNFRII/Fc protein (results
ersham, Arlington Heights, IL), were added to each cul-
not shown).
ture. The medium was collected 3 hr later. Cells in the
medium were removed by centrifugation (1000 rpm for Binding assays
10 min at 47, in a Sorvall H1000B rotor). The medium was
then concentrated 50-fold by centrifugation (5000 rpm TNF was radioiodinated by a solid phase method (Io-
dogen, Pierce, St. Louis, MO) to a specific activity of 3for 8 hr at 47, in a Sorvall SS34 rotor) in a Centricon-3
concentrator (Amicon, Beverly, MA). Protein samples 1 1015 cpm/mmol with full retention of biological activity,
as measured in a standard L929 fibroblast cytolytic assayfrom concentrated culture fluids were mixed with an
equal volume of a protein loading solution (120 mM Tris – (below). Ligand blots were performed as described (Hu et
al., 1994). Briefly, Fc fusions of CrmC and soluble humanHCl, pH 6.8, 20% glycerol, 4% SDS, 5% b-mercaptoetha-
nol, and 0.02 mg/ml bromophenol blue), and solubilized TNFRII were electrophoresed through an 8–15% SDS gel
under nonreducing conditions, transferred to nitrocellu-by boiling for 3 min. The solubilized proteins were re-
solved by electrophoresis through a 15% polyacrylamide lose, blocked with Binding Media A (PBS, 4% BSA, 0.1%
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NaN3 , 1% nonfat dry milk), probed with
125I-muTNF (1 nM,
31 1015 cpm/mmol), and the labeled complexes detected
by phosphorimaging (Molecular Devices, Palo Alto, CA).
14C-labeled marker proteins were obtained from Amer-
FIG. 1. The position of the crmB and crmC genes in genome of CPVsham.
(Brighton Red strain). A PstI restriction map of the 220-kbp genomic
Equilibrium binding isotherms of 125I-muTNF and a mu- DNA is shown (Mackett and Archard, 1979; Pickup et al., 1984). One
rine thymoma subclone, EL4-3/, were determined by copy of the crmB gene is located in each of the identical pstI K frag-
standard methods and plotted using a Scatchard format ments present in the inverted terminal repeats (Hu et al., 1984). The
crmC gene is located within the PstI J fragment. The arrows indicate(Smith et al., 1990). Briefly, a murine thymoma subclone,
the orientations in which these genes are transcribed.EL4-3/, containing 2400 TNF receptors, was used as
the cellular target for 125I-muTNF. Two million cells were
incubated for 2 hr, 47, with increasing concentrations RESULTS
of 125I-muTNF in Binding Media B (RPMI 1640, 100 mM
Cowpox virus possesses a second gene, crmC,HEPES, 3% BSA, 0.1% NaN3 , pH 7.4) in a total volume of
encoding a protein with homology to the ligand-150 ml. Duplicate 60-ml aliquots were withdrawn, micro-
binding domains of TNF receptorsfuged through pthalate-oil tubes, and tubes cut to mea-
sure free (top) or bound (bottom) 125I-muTNF in a g-
The WR and Copenhagen strains of vaccinia virus
counter. Competitive inhibition assays were performed
each contain open reading frames that appear to be
similarly (Goodwin et al., 1991), with 0.1 nM 125I-muTNF
remnants of a longer open reading frame of a functional
incubated with cells and increasing concentrations of
gene that once encoded a TNF receptor homologue dif-
unlabeled inhibitors (TNFRII/Fc or CrmC/Fc). Data was
ferent from the CrmB protein. These open reading frames
fitted to a single-site competitive inhibition equation (Park
include those designated SalI F19R and HindIII A53R
et al., 1987). Slide autoradiography was used to assess
(Howard et al., 1991; Goebel et al., 1990). A comparison
CrmC/Fc or TNFRII/Fc binding to cell surface targets
of restriction maps of the cowpox virus genome (Pickup
transiently expressed in CV1/EBNA cells (Gearing et al.,
et al., 1984) with maps generated from the sequence of
1989; Smith et al., 1993). Binding detection was enhanced
the vaccinia virus genome suggested that the corre-
by amplification with radioiodinated (11 1016 cpm/mmol)
sponding location of these open reading frames in the
goat anti-human Fc (Jackson ImmunoResearch, West
cowpox virus genome is within the 1.35-kb PstI–ClaI
Grove, PA).
fragment about 48 kilobases from the right end of the
cowpox virus genome (Fig. 1).Cytolytic assays
To determine if this region of the cowpox virus genome
Cytolytic assays used mouse L929 cell targets, murine contains a gene encoding a functional version of a TNF
TNF or human LTa as cytotoxic agents, and recombinant receptor, the nucleotide sequence of the 1.35-kb PstI–
purified CrmC/Fc or huTNFRII/Fc as inhibitors. Death ClaI fragment was determined (Fig. 2). The nucleotide
was assessed by the crystal violet indicator (Mohler et sequence analysis showed that this PstI–ClaI fragment
al., 1993). Briefly, 2 1 104 L929 cells were plated in 96- contains an open reading frame capable of encoding a
well trays (Costar) in a total volume of 100 ml media and 186-amino acid protein sharing significant similarity to
incubated overnight at 377 in 5% CO2 atmosphere. Spent the TNF binding domains of TNF receptors. This open
media was then removed, and media containing 1 ng/ml reading frame comprises the coding region of a gene
muTNF (30 ng/ml huLTa), in the presence or absence of designated crmC. The ORF is shown schematically in
serial dilutions of inhibitors, was added. Actinomycin D Fig. 3A, emphasizing domain structure (see also Fig. 12),
(5 mg/ml) was present in all wells. The constant amount and as a hydropathy plot in Fig. 3B, delineating the hy-
of 1 ng/ml TNF (huLTa) which produced 100% cytolysis drophobic N-terminal signal sequence. No internal hy-
in this assay was determined from previous experiments. drophobic element is present.
After 12 hr of incubation, cells were washed 31 with PBS
and stained for 10 min with 100 ml of 0.5% crystal violet in The crmC gene is transcribed during the late phase
methanol/water (1/4). Plates were washed with distilled of virus replication
water, and the indicator was solubilized with 2% sodium
Primer extension and S1 nuclease protection analysesdeoxycholate. All assays were performed in triplicate.
were used to characterize the transcription of the crmCAbsorbance (A) at 570–630 nm was determined in a
gene. The 5* ends of the crmC RNA transcripts weremicroplate reader (Molecular Devices, Palo Alto, CA),
first characterized by primer extension analyses, usingand percentage of cytotoxicity (C) was quantified by the
unfractionated RNA extracted from virus-infected cells,following formula:
and the A53R1 primer, as described under Materials and
%C
Methods. RNAs were extracted from cowpox virus-in-
fected cells both at early times (3 hr postinfection) and at [A (control well) 0 A (test)]/[A (control well)] 1 100.
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FIG. 2. The nucleotide sequence of the PstI–ClaI fragment of cowpox virus DNA containing the crmC gene. The predicted amino acid sequences
encoded by the ORFs and the crmC gene are indicated beneath the nucleotide sequence. The two ORFs, orfA and orfB, closely resemble the 3*
end of the A52R ORF and the 5* end of the A55R ORF present in the genome of the Copenhagen strain of vaccinia virus (Goebel et al., 1990). The
other long ORF is that of the crmC gene. The underlined sequence 5* TAAAT 3* is the transcriptional start site of the crmC gene. The entire
sequence has been assigned GenBank Accession No. U55052.
late times (16 hr postinfection) during the viral replication. ends of the crmC RNAs and the template DNA. A 32P-
labeled probe was generated by PCR, amplifying a 400-Transcripts of the crmC gene were detected at late times
after infection (Fig. 4, lane L), but not at early times after bp DNA fragment from p1464 template using 32P 5*-end
labeled A53R1 primer (the same primer was used in theinfection (lane E). Most of the 3* ends of the cDNAs
generated from late RNAs correspond to a sequence at above primer extension experiment) and the SP6 univer-
sal primer (Promega, Madison, WI). This DNA probe wasleast 4 nucleotides upstream of the sequence 3* ATTTA
5* (template strand, corresponding to nucleotides 208 – hybridized with unfractionated late RNAs extracted from
infected cells 16 hr postinfection. After S1 nuclease di-212 in Fig. 2) consistent with the expected 5* end struc-
ture of 5*-polyadenylated mRNAs transcribed from late gestion, a single major protected product (Fig. 5, lane L)
was detected. The size of this product indicates that thepromoters containing the sequence 3* ATTTA 5* at the
transcriptional start-site (Bertholet et al., 1987; Schwer et complementarity between the 5* ends of the crmC RNAs
and the DNA template extends to the sequence 3* ATTTAal., 1987; Patel and Pickup, 1987; Wright and Moss, 1987).
5* (complementary to nucleotides 208–212 in Fig. 2).S1 nuclease protection analysis was performed to de-
termine the extent of complementarity between the 5* These results show that the crmC is transcribed during
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FIG. 3. Domain structure and hydrophathy plot of CrmC. (A) domain substructure of CrmC is schematized in blocks: L (signal sequence, 21 amino
acids); D1-D4, four homologous domains, each containing about 40 amino acids and six cysteines; SP, 14 residue spacer, not part of D1. D4 is
truncated, containing only 28 residue. N & C denote amino and carboxyl termini. See also Fig. 12. (B) Hydropathy plot (Kyte and Doolittle, 1982),
predicting a hydrophobic N-terminus.
the late phase of the virus replication cycle from a late
promoter including the sequence 3* ATTTA 5* (template
strand) at the transcriptional start site required to direct
5* polyadenylation (Bertholet et al., 1987; Schwer et al.,
1987; Patel and Pickup, 1987; Wright and Moss, 1987).
The majority of the primer extension products are 8– 12
nucleotides longer than the S1 protection product (Figs.
4 and 5), suggesting that about 8–12 adenylates are
present at the 5* ends of most of the crmC RNA tran-
scripts.
The predicted site of transcriptional initiation is about
150 bp upstream of the coding region of the crmC gene.
Five potential initiation codons are present between this
transcriptional start site and the predicted initiation co-
don of the crmC gene (Fig. 2). Four of these are not in
an optimal context for efficient translation initiation as
predicted by Kozak (1989). The fifth potential initiation
codon (the third ATG downstream of the transcriptional
start site) initiates an open reading frame of only 3 co-
dons terminated 65 nucleotides upstream of the initiation
codon of the crmC gene. Therefore, the 5 potential initia-FIG. 4. Primer extension mapping of the 5* ends of the RNA transcript
of the crmC gene. The primer used is a 18-mer (A53R1) 5*-ATAGTACAT- tion codons in the leader of the mRNA may not adversely
ACAGTCAGC-3* which is exactly complementary to the sequences affect the efficiency of translation of the crmC gene.
between nucleotides 374 and 391 shown in Fig. 2. This primer was 5*- In addition to the functional late promoter, which re-
end labeled with 32P and annealed to the RNAs extracted from cells
sembles the consensus sequence of late promoters, theinfected with CPV. The annealed primer was extended by AMV reverse
sequence upstream of the coding region of the crmCtranscriptase. The primer-extended products were resolved by electro-
phoresis in a 6% polyacrylamide gel containing 8 M urea and then gene contains a sequence 5*-GAAAAATATATT-3* (Fig. 2,
visualized by autoradiography. Lane E is the extended product using nucleotides 248–259), resembling the consensus se-
unfractionated early RNAs extracted at 3 hr postinfection from CPV- quence for poxviral early promoters (Davison and Moss,
infected cells. Lane L shows the extended products using unfraction-
1989a,b; Ink and Pickup, 1989). However, two early tran-ated late RNAs extracted at 16 hr postinfection from CPV-infected cells.
scription termination signals are present in the sequenceThe size markers (lanes A,G,C, and T) beside lanes E and L are the
dideoxy chain-termination products using the same primer as in the 5*-TTTTTTTAT-3* (Rohrmann et al., 1986), 61 nucleotides
primer extension and p1464 plasmid DNA, which contains the entire downstream of this putative early promoter and 28 nucle-
crmC gene, as template. The template strand DNA sequences around
otides upstream of the initiation codon of the crmC genethe predicted crmC RNA start site is shown. The length of the extension
(Fig. 2). This suggests that any early RNAs transcribedproducts extends to the GTTT () region. The 5* ATTTA 3* region is
indicated by *. from the potential early promoter would terminate within
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the first 30 nucleotides of the coding region of the crmC
gene, consistent with the failure to detect either early
crmC mRNAs or the synthesis and secretion of any CrmC
protein during the early phase of virus replication.
The cowpox virus CrmC protein is secreted from
infected cells during the late phase of virus
replication
To identify the protein encoded by the crmC gene,
and also to examine the effects of this protein on virus
replication in the chorioallantoic membrane of chick em-
bryos, three recombinant viruses were constructed, as
follows. A recombinant vaccinia virus (A555) was con-
structed by inserting the crmC gene of cowpox virus
into the thymidine kinase gene of the vaccinia virus. A
FIG. 6. The crmC gene encodes a soluble protein secreted fromrecombinant cowpox virus (A512) was constructed in
virus-infected cells at late times. Virus-infected 143 cells (3.1 1 106)which the crmC gene was deleted by replacement with were labeled with 100 mCi [35S]cysteine (1300 Ci/mmol) in 2 ml cysteine-
free MEME without serum from 11 to 14 hr postinfection. Labeled
secreted proteins were concentrated 50-fold and resolved by 15% SDS–
PAGE. The radiolabeled proteins were visualized by autoradiography
of the dried gel. Lane A, 14C-labeled molecular mass standards (Amer-
sham, Arlington Heights, IL); the molecular masses of these proteins
are indicated in kDa. Lanes B–F contain secreted proteins from cells
infected with: lane B, wild-type vaccinia virus (lacking the crmC gene);
lane C, vaccinia virus A555 (containing the CPV crmC gene); lane D,
wild-type CPV; lane E, CPV A512 (lacking the crmC gene); lane F,
CPV A513 (lacking the crmB and crmC genes). The CrmC proteins are
secreted from cells infected with either the wild-type CPV (lane D) or
the vaccinia virus A555 (lane C).
E. coli lacZ gene. A second recombinant cowpox virus
(A513) was constructed in which the crmC gene and the
two copies of the crmB gene are inactivated.
To assay for the synthesis and secretion of products
of the crmC gene, proteins synthesized in cells infected
with either vaccinia virus A555, cowpox virus A512, or
cowpox virus A513 were metabolically labeled with [35S]-
cysteine from 11 to 14 hr after infection. The proteins
present in the culture fluids of these cells were thenFIG. 5. Nuclease S1 protection analysis of the 5* ends of the crmC
concentrated and resolved by electrophoresis in 15%transcripts. A 400-bp DNA fragment (with the 5* ends of the nucleotide
391 labeled with 32P) between nucleotides 1 and 391 (Fig. 2) was polyacrylamide gels (Fig. 6). Insertion of the cowpox virus
obtained by PCR. This 32P-labeled 400-bp DNA fragment was used as crmC gene into the genome of vaccinia virus results in
probe to anneal with RNAs extracted from cells infected with CPV. the generation of a secreted protein of about 25 kDa (Fig.
Residual single-stranded nucleic acids were digested with S1
6, lane C), which is not synthesized in cells infected withnuclease, and the nuclease-resistant products resolved by electropho-
wild-type vaccinia virus (lane B). A lesser quantity of aresis in a 6% polyacrylamide gel containing 8 M urea. DNA fragments
protected from digestion were visualized by autoradiography of the protein of an apparent molecular mass of 26 kDa was
dried gel. Lane L shows the protection products using unfractionated also detected. These two proteins were also evident in
RNA extracts from late CPV-infected cells 16 hr postinfection). Lanes culture fluids of cells infected with wild-type cowpox virus
AGCT contain the dideoxy chain-termination products using the same
(lane D), but not in culture fluids from cells infected withprimer A53R1 as in the primer extension and p1464 DNA, contains the
either cowpox virus A512 (lane E) or cowpox virus A513entire crmC gene, as template. This A53R1 primer was also one of the
primers (/ nucleotide 391, Fig. 2) used to generate the above protection (lane F), each of which lack intact copies of the crmC
probe. The longer nuclease-resistant product present in Lane L is resid- gene. These data suggest that the crmC gene encodes
ual full-length probe DNA. The template strand DNA sequence around a secreted protein whose apparent molecular mass is
the predicted crmC RNA start site is shown. The size of the protection
about 25 kDa. The molecular mass of the mature CrmCproduct indicates that the complementarity between the 5* end of the
protein predicted from the amino acid sequences is 18crmC RNa and its template DNA matches to the ATTTA region (*),
which corresponds to the region from nucleotide 208 to 212 in Fig. 2. kDa, suggesting that posttranslational modifications, par-
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FIG. 7. SDS gels and ligand blot of purified CrmC/Fc and TNFRII/Fc. (A) SDS gels (8–15%) of CrmC/Fc and TNFRII/Fc under reducing (lanes 1
and 2) and nonreducing (lanes 3 and 4) conditions. Molecular mass markers appear on either side. (B) Ligand blot of TNFRII/Fc (left) and CrmC/
Fc (right) probed with 1 nM 125I-muTNF. Lanes 2 and 4 included no inhibitors; Lanes 1 and 5 included a 1001 molar excess of unlabeled muTNF;
Lanes 3 and 6 included a 2001 molar excess of huLTa; Lane 7 included a cocktail of 13 different cytokines (see Materials and Methods), each at
1001 molar excess.
ticularly glycosylation at one or both of the two potential inhibited 125I-muTNF binding to TNFRII (lane 3), it did not
N-glycosylation sites (Fig. 2), does occur. reduce binding to CrmC (lane 6).
To quantitate TNF binding to CrmC/Fc, Scatchard anal-
CrmC specifically binds TNF but not LTa ysis and competitive inhibition binding isotherms were
determined using murine EL4 3/ cells. The affinity (Kd)In order to more easily analyze the binding properties
of 125I-muTNF for murine TNF receptors was 200 pM,of CrmC, a chimera (CrmC/Fc) was constructed by fusing
with approximately 2400 sites (Fig. 8A). Both unlabeledthe Fc region of human IgG1 to the C-terminus of mature
muTNF and unlabeled CrmC/Fc completely inhibited 0.1CrmC, and expressed in CV1/EBNA cells (see Materials
nM 125I-muTNF binding to EL4 3/ cells with a Ki of 200and Methods). For control experiments, a similar construct
pM in each case (Fig. 8B). The affinity of CrmC/Fc forof the extracellular region of human TNFRII (huTNFRII/Fc)
muTNF is thus identical to that of muTNF for murinewas also made. Figure 7A displays SDS–PAGE of purified
cellular receptors. Since the failure of huLTa to bindrecombinant CrmC/Fc and TNFRII/Fc proteins under re-
CrmC might simply reflect species-specific differences,duced (lanes 1 and 2) and nonreduced (lanes 3 and 4)
a cell surface form of muLTa was constructed to assessconditions. Both proteins show protomeric molecular
binding in more sensitive assays. The chimera fuses theweights under reduced conditions consistent with their
sequence of mature muLTa to the C-terminal (nonrecep-sequences (55 kDa, CrmC/Fc; 67 kDa, TNFRII/Fc) and
tor binding) portion of human pro-TNF containing intra-approximately twofold higher molecular weights under
cellular, transmembrane, and ‘‘spacer’’ elements (seenonreduced conditions (110 kDa, CrmC/Fc; 140 kDa,
Materials and Methods). The chimera (surmuLTa) is thusTNFRII/Fc), consistent with native dimeric structures. To
a type II membrane protein, similar to all TNF ligandimmediately assess potential TNF binding properties, both
family members (except LTa, classically a secreted pro-Fc proteins were electrophoresed through nonreducing
tein), and has the absolute binding specificity of muLTa.SDS gels and ligand blotted with 125I-muTNF in the pres-
To test binding, human pro-TNF and surmuLTa were sep-ence or absence of a 100-fold molar excess of unlabeled
arately expressed transiently in CV1/EBNA cells, and in-competitive inhibitors (Fig. 7B). Both proteins bound 125I-
cubated with either TNFRII/Fc or CrmC/Fc for 30 min atmuTNF (lanes 2 and 4). The binding is specific for two
room temperature. The adherent cells were washedreasons. First, inclusion of unlabeled muTNF completely
twice with PBS and then incubated with 125I-goat anti-blocked 125I-muTNF binding (lanes 1 and 5); second, inclu-
huFc F(ab*)2 fragments. The bound CPM are displayedsion of a cocktail of 13 unlabeled cytokines (huIL1a, hu-
in Fig. 9. CV1/EBNA cells expressing huPro-TNF boundIL1b, huIL2, huIL4, huIL6, huIL7, huIL8, huIL15, huGM-
both TNFRII/Fc and CrmC/Fc. In contrast, CV1/EBNA-CSF, huG-CSF, huTGFb, hug-IFN, and huNGF; each at
surmuLTa cells specifically bound high levels of TNFRII/100-fold molar excess) failed to show detectable inhibition
Fc only; CrmC/Fc bound only at the nonspecific back-(lane 7). Human TNF, radioiodinated to carry-free status
ground levels of mock-transfected cells. To assess bind-without loss of biological activity, also bound CrmC/Fc and
ing in an extraordinarily sensitive format, slide autoradi-TNFRII/Fc, and unlabeled huTNF completely eliminated
ography was employed of similarly transfected cells (seebinding (Mohler et al., 1993; Smith et al., 1991; and data
not shown). However, while unlabeled huLTa completely Materials and Methods). Photomicrographs of the auto-
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FIG. 8. Equilibrium binding isotherms of muTNF and CrmC/Fc. (A) Binding isotherms of 125I-muTNF to murine EL4 3/ cells reveals 2400 sites/
cell with an affinity of 200 pM. EL4 3/ cells (5.2 1 107 cells/ml) were incubated with varying concentrations of 125I-muTNF for 2 hr, 47. Binding was
assayed as described under Materials and Methods. Inset shows Scatchard representation of specific binding replotted from (A). Data are corrected
for nonspecific binding, measured in the presence of a 200-fold molar excess of unlabeled muTNF. (B) Inhibition of 125I-muTNF binding EL4 3/ cells
by unlabeled muTNF (l) or CrmC/Fc (s). EL4 3/ cells (4 1 107 cells/ml) were incubated with 125I-muTNF (0.1 nM) and varying concentrations of
unlabeled muTNF or CrmC/Fc for 2 hr, 47. Binding was assayed as described under Materials and Methods. The continuous curves passing through
the data were calculated from a one-site competitive inhibition equation using a Ka value for 125I-muTNF of 5 1 109 M01. Both muTNF and CrmC/
Fc gave complete inhibition of binding, with nearly identical inhibition constants (Ki  200 pM). All data corrected for nonspecific binding measured
in the presence of 2 1 1008 M unlabeled muTNF.
radiographic results confirm that while both CrmC/Fc and ligand family, transiently and individually expressed in
CV1/EBNA cells. These include: huCD27 ligand (CD27L),TNFRII/Fc clearly bind cells expressing human pro-TNF
(Figs. 10A and 10C), only TNFRII/Fc bound surmuLTa (Fig. human and muCD30L, human and muCD40L, human and
mu4-1BBL, human and muOX40L, human and muFasL,10B). CrmC/Fc showed no binding to surmuLTa (Fig. 10D).
Taken together, these results provide strong evidence muLTa/muLTb complexes, human and muLTb, and hu-
man and muTRAIL (Smith et al., 1994; Wiley et al., 1995).that CrmC possesses binding sites for TNF, but not for
LTa. Slide autoradiography was also used to test CrmC No binding was detected to CrmC/Fc. All ligands were
expressed, however, because control binding to theirbinding to all other presently known members of the TNF
normal Fc/cognates was abundant (results not shown).
CrmC completely inhibits muTNF, but not huLTa-
mediated cytotoxicity
To examine inhibition of biological activity, murine TNF
or huLTa-mediated cytotoxic assays using murine L929
cell targets were performed. MuTNF and huLTa titered
normally (Figs. 11A and 11B), and the human IgG1 nega-
tive controls showed no inhibition of this lytic activity.
Both TNFRII/Fc and CrmC/Fc completely inhibited
muTNF-mediated cytolysis in a dose-dependent manner,
with CrmC/Fc roughly threefold more potent to 50% killing
(Fig. 11A). In contrast, while TNFRII/Fc clearly also inhib-
ited huLTa-mediated killing, CrmC/Fc failed to show any
inhibition (Fig. 11B).
The crmC gene is not required for the production of
FIG. 9. CrmC/Fc and TNFRII/Fc Binding to CV1/EBNA cells express- red pocks in the chorioallantoic membrane of the
ing huPro-TNF or surmuLTa. CV1/EBNA cells were transfected with 2.5 chick embryo
mg of plasmid containing relevant inserts and probed 2 days later
with CrmC/Fc or TNFRII/Fc followed by 125I-goat anti-huFc F(ab*)2 (see To determine if the crmC gene is required for the for-
Materials and Methods for details). Cells were washed three times mation of the red pocks characteristic of cowpox virus
with PBS and specifically bound CPM was determined. CrmC/Fc and infection of chorioallantoic membranes of chick embryos,
TNFRII/Fc specifically bound CV1-proTNF, but only TNFRII/Fc bound
the morphologies of the pocks produced by cowpox virussurmuLTa. Mock indicates background binding of CV1/EBNA cells trans-
A512 (in which the crmC gene is deleted) were examined.fected with plasmid lacking inserts. Vertical brackets represent stan-
dard errors of quadruplicate assays. Three days after infection, simple visual inspection did
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FIG. 10. Slide autoradiographs of CV1/EBNA cells transiently expressing huPro-TNF or surmuLTa probed with CrmC/Fc or TNFRII/Fc. CV1/EBNA
cells were transfected with 2.5 mg of plasmid containing relevant inserts, probed 2 days later with CrmC/Fc or TNFRII/Fc followed by 125I-goat anti-
huFc F(ab*)2 , and autoradiographed (see Materials and Methods). Pro-TNF binds both CrmC/Fc (A) and TNFRII/Fc (C), as shown by dark silver
grains over cells expressing the insert. TNFRII/Fc (B) but not CrmC/Fc (D) binds surmuLTa. All magnifications are 1700.
not reveal any marked differences between the red pocks 137 pocks produced the wild-type cowpox virus, 135
(99%) were red, and 2 (1%) were white. Therefore, theproduced by the recombinant virus lacking the crmC
gene and those produced by the wild-type cowpox virus. crmC gene is not necessary for the production of red
pocks by cowpox virus. The few white pocks producedOf 465 pocks produced by the A512 virus, 460 (99%) of the
pocks were red, and 5 (1%) were white. By comparison, of by either cowpox virus A512, or the wild-type cowpox
FIG. 11. Inhibition of muTNF or huLTa-mediated cellular cytotoxicity with CrmC/Fc or TNFRII/Fc. (A) Murine L929 cell (2 1 104) were exposed to
serial dilutions of muTNF alone (2 mg/ml initial) or to a constant amount of muTNF (1 ng/ml) in the absence or presence of titered huIgG1, TNFRII/
Fc, or CrmC/Fc (all 2 mg/ml initial) for 12 hr at 377. Death was assessed by crystal violet staining as described under Materials and Methods.
Murine TNF titered normally (n), and IgG1 (L) did not inhibit TNF-mediated cytolysis. CrmC/Fc (s) and TNFRII/Fc (h) both inhibited TNF-mediated
killing in a dose-dependent manner, with CrmC/Fc about threefold more active. (B) Murine L929 cells were incubated with serial dilutions of huLTa
alone (2 mg/ml initial) or to a constant amount of huLTa (30 ng/ml) in the absence or presence of titered huIgG1, TNFRII/Fc, or CrmC/Fc. Cytolysis
was tested as in (A). HuLTa titered normally (n), and huIg1 (L) gave no inhibition. TNFRII/Fc (h) inhibited huLTa-mediated killing in a dose-
dependent manner, but CrmC/Fc (s) failed to show any inhibition.
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virus, were probably produced by variants generated The primary structure of CrmC contains cysteine-rich
fourfold pseudorepeats, and is homologous to all mem-spontaneously through genome rearrangements that re-
sulted in the loss of genes such as the crmA gene and bers of the TNF receptor family, including TNFRI, TNFRII,
CD30, 4-1BB, Fas, CD27, OX40, CD40, the poxviral TNFthe ps/hr gene, which are essential for red-pock forma-
tion (Archard et al., 1984; Pickup et al., 1984, 1986; Marti- binding proteins SFV T2, MV T2, CPV CrmB, and the
variola G4R (G2R) ORF (Fig. 12). These pseudorepeatsnez et al., 1993).
Pocks produced in CAMs infected with vaccinia virus are crystallographic domains (Banner et al., 1993), al-
though the fourth domain of CrmC is truncated. TheA555 (containing an expressed cowpox virus crmC gene)
were also examined by visual inspection. Three days strongest sequence homology to CrmC is with the extra-
cellular (ligand-binding) region of cellular TNFRII, and theafter infection, no significant differences were detected
between the white pocks produced by the recombinant N-terminal 170 residues of CPV CrmB (SFV T2, MV T2)
and the variola G4R (G2R) ORF. Because of the cysteine-virus A555 and those produced by the wild-type vaccinia
virus. These results suggest that although the crmC gene rich nature of the proteins, this is most clearly seen by
pairwise sequence alignments of CrmC with other mem-may contribute to the viral inhibition of TNF-mediated
host defenses, it is neither necessary nor sufficient for bers using the Align program of the National Biomedical
Research Foundation (Genetics Computer Group, 1991).the generation of red pocks in CAMs during the first 3
days after infection. CrmC and CrmB, for example, show an Align score 13
standard deviations (SD; 32% identity) above the mean
The inactivation of the cowpox virus crmB and crmC score for an ensemble of randomly permuted sequences
genes does not affect the pock morphology on CAMs of the same lengths and amino acid composition. Scores
greater than 3.0 are considered significant, indicatingRed pocks are formed on CAMs infected with cowpox
common ancestry. CrmC and muTNFRII also score 13viruses lacking either the crmB genes (Hu et al., 1994)
SD, while CrmC and muTNFRI score 6 SD (26% identify).or the crmC gene. However, this apparent lack of effect
These results are consistent with the observed CrmCof either gene on pock morphology might occur because
ligand specificity for TNF, and suggest CrmC, like CrmB,each of these TNF receptor genes renders the other gene
represents an acquired form of the ligand binding regionredundant. To test this possibility, a recombinant cowpox
of cellular TNFRII (Smith et al., 1990, 1991; Smith andvirus (A513) lacking the crmC gene and the two crmB
Goodwin, 1995). However, CrmC does not show asgenes was constructed. Pocks produced on CAMs in-
strong a sequence similarity to cellular TNFRII as doesfected with either cowpox virus A513 or wild-type cowpox
CrmB; the TNFRII/CrmB (and TNFRII/G4R ORF) Alignvirus were compared by visual inspection. Three days
score is 21 SD.after infection, no significant differences were detected
Three other (disrupted) vaccinia ORFs, C22L (Copen-between the red pocks produced by the cowpox virus
hagen), A53R (Copenhagen), and Sal 19R (WR) appearA513 and those produced by the wild-type cowpox virus.
in the literature. The location in the ITRs of C22L (dupli-Of 384 pocks produced by the A513 virus, 379 (98.7%)
cated as B8R in the right ITR), its dominant homology towere red, and 5 (1.3%) were white. By comparison, as
SFV T2, MV T2, and CrmB, as well as the identificationnoted above, of 137 pocks produced by the wild-type
of further downstream elements as discontinous ORFscowpox virus, 135 (99%) were red, and 2 (1%) were white.
which, when concatenated, resemble the C-terminal halfThese results show that although the CrmB and CrmC
of T2 (CrmB), convincingly demonstrate this ORF to beproteins of cowpox virus may interfere with the TNF-
part of a disrupted T2 (crmB) locus (Smith and Goodwin,mediated host antiviral defenses, neither the CrmC pro-
1994). A53R and Sal 19R, in contrast, are not ITR-local-tein, nor the CrmB protein, either in the presence or ab-
ized, are virtually identical in sequence, and are 95%sence of the other protein, is required for cowpox virus
identical to CrmC (Fig. 12). Thus, these ORFs appear toto generate red pocks in the CAMs of chick embryos.
represent disrupted forms of the crmC, not crmB, locus.
The known poxvirus variants of CrmB and CPV CrmC areDISCUSSION
schematized in Fig. 13 together with cellular TNFRII, their
presumed progenitor.The single copy crmC gene encodes a protein of 186
amino acids, with a hydrophobic N-terminus of 21 resi- The presumed function of CrmC is viral inhibition of
host TNF, consistent with its ability to completely blockdues and two potential N-linked glycosylation sites, indi-
cating it is a secreted glycoprotein. Detection of CrmC TNF-mediated cellular cytotoxicity in vitro. As antiviral
effects of TNF (both soluble TNF and its surface pro-with an apparent MW of 25 kDa in supernatants from
cowpox-infected cells, or cells infected with vaccinia vi- form) are well established (Beutler, 1992), the presence
of CrmC would no doubt confer a strong selective advan-rus expressing CPV CrmC, clearly establishes these fea-
tures. It is also consistent with the abundant secretion of tage to the pathogen producing it. CrmC is thus structur-
ally and functionally homologous to soluble forms of cel-recombinant CrmC/Fc, constructed with the CrmC native
viral leader sequence, from transfected CV1/EBNA cells. lular TNFRII released through proteolytic cleavage fol-
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FIG. 12. Amino acid alignment of the cysteine-rich fourfold pseudorepeats (domains) of CPV CrmC, vaccinia poxviral analogues (Sal 19R, WR
strain; A53R, Copenhagen strain), CPV CrmB, and murine TNF receptors I and II. Cysteine residues are shown in reverse contrast and residues
conserved in at least three family members are shaded. Arrows under Sal 19R and A53R indicate frameshifts required to complete homologous
region of ORF. Asterisks (*) indicate stop codons (overridden to extend A53R and Sal 19R ORFs). Disulfide linkage pattern shown based on crystal
structure of human TNFRI. Parenthetical numbers at N- and C-termini refer to positions as cited in original references. Potential N-linked glycosylation
sites are in bold. CrmC also contains a second such site present in the N-terminal spacer region not shown (Fig. 2).
FIG. 13. Schematic comparing poxviral TNF receptors and cellular analogue, TNFRII. SFV-T2 (Shope Fibroma virus T2), MV-T2 (myxoma virus
T2), and CPV-CrmB (cowpox virus CrmB) are analogous gene products. CPV-CrmC is encoded by a distinct locus. Variola virus G4R (VarV-G4R;
strain India-1967) is an intact ORF (G2R in strain Bangladesh-1975 differs by a single amino acid) whose putative protein has not yet been
characterized (Massung et al., 1993; Shchelkunov et al., 1993). Homologous domains are shown as open boxes and cysteine residues by horizontal
lines. Number of amino acids in conserved C-terminal regions are indicated. Asterisks (*) indicate potential N-linked glycosylation sites. CrmC also
possesses a second such site in the spacer region (not shown).
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lowing immune stimuli. Soluble forms of many cytokine secreted protein, can also be found in cell surface forms,
complexed with lymphotoxin b (LTb), another TNF ligandreceptors, either shed or alternatively spliced, are a com-
mon phenomena following activation of the immune sys- family member (Browning et al., 1993). At least one form
has a specific receptor, TNFR-RP (Crowe et al., 1994).tem, and are widely believed to act as negative feedback
loops by binding ligand and preventing interaction with CrmC, if it could bind LTa like CrmB, might also bind
and inhibit biological activities of these complexes. Thus,cognate cellular receptors (Mohler et al., 1993). The pre-
cise mechanisms of CrmC (and CrmB) action, however, CrmC may have instead acquired a selective advantage
by eliminating binding sites for LTa/LTb complexes,are still unclear. It remains an interesting possibility, for
example, that in certain cells these proteins function as while retaining sites for TNF. CrmC would leave un-
checked the biological activity of LTa/LTb oligomersintracellular inhibitors. In macrophages, surely among
the earliest host cells infected and the dominant source while retaining inhibition of the (antiviral) TNF activity.
No biological activities of these complexes have as yetof TNF, these viral products might bind de novo pro-TNF,
preventing its cellular egress. In the case of CrmB, similar been reported, so it is not clear how they might contribute
to virulence.arguments would also apply to the expression of surface
LTa/LTb heterologous complexes known to be present The major unresolved question remains: why would
CPV encode two distinct TNF inhibitors, CrmB andon T cells, B cells, and NK cells (Browning et al., 1993).
TNF (or LTa/LTb) production would be shut off at the CrmC? Clearly, however, they are not identical. Although
both inhibit TNF action, only CrmB binds LTa. CrmB issource, effecting the most profound inhibition. Moreover,
soluble TNFRI, in the absence of ligand, has been shown diploid and expressed at early times while crmC is a
single copy gene and appears at late times. Further,to form dimers at high concentrations in solution, one
form of which appears still capable of binding TNF (Nai- CrmB contains a highly conserved C-terminal element
(159 amino acids) absent from CrmC, and the functionsmith et al., 1995). It is formally possible, therefore, that
in the intracellular environment of a poxvirus-infected of this domain, no doubt containing a binding site for
unknown proteins, has yet to be deciphered.cell, CrmC or CrmB might also so dimerize, effecting the
same end.
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regards to CrmB. First, CrmB and CrmC are encoded by
precisely the same virus, and CrmB has clearly been
REFERENCESshown to bind both mouse and human TNF and LTa.
Second, radioiodinated probe binding in an autoradio- Alcamı´, A., and Smith, G. L. (1992). A soluble receptor for interleukin-
graphic format is an almost infinitely sensitive assay, 1b encoded by vaccinia virus: a novel mechanism of virus modulation
of the host response to infection. Cell 71, 153–167.easily allowing detection with affinities in the mM range
Archard, L. C., Mackett, M., Barnes, D. E., and Dumbell, K. R. (1984).(Smith et al., 1995b). Yet CrmC shows no detectable bind-
The genome structure of cowpox virus white pock variants. J. Gen.ing to muLTa in this assay or to huLTa in receptor blots.
Virol. 65, 875–886.
CrmC also does not inhibit huLTa-mediated cytotoxicity. Aviv, H., and Leder, P. (1972). Purification of biologically active globin
Third, a recent epidemiological study of the cowpox virus messenger RNA by chromatography on oligothymidylic acid-cellu-
lose. Proc. Natl. Acad. Sci. USA 69, 1408–1412.strongly suggests the natural host is the field mouse
Banner, D. W., D’Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.-J., Broger,(Crouch et al., 1995), suggesting murine, not human cyto-
C., Loetscher, H., and Lesslauer, W. (1993). Crystal structure of thekines are the most physiologically relevant. One possibil-
soluble human 55 kd TNF receptor-human TNFb complex: implica-
ity is that CrmC lost its ancestral LTa binding site be- tions for TNF receptor activation. Cell 73, 431–445.
cause there was no selective advantage to retain it. This Bertholet, C., Van Meir, E., ten Heggeler-Bordier, B., and Wittek, R.
(1987). Vaccinia virus produces late mRNAs by discontinuous synthe-is surprising because: (1) the most likely function of CrmC
sis. Cell 50, 153–162.is viral inhibition of host produced (viral-elicited) TNF,
Beutler, B. (1992). ‘‘Tumor Necrosis Factors: The Molecules and Theiryet TNF and LTa are normally both produced during an
Emerging Role in Medicine.’’ Raven Press, New York.
immune response and show similar activities (Beutler, Browning, J. L., Ngam-ek, A., Lawton, P., De Marinis, J., Tizard, R., Chow,
1992). In fact, CrmB inhibits both TNF and LTa cytolytic E. P., Hession, C., O’Brine-Greco, B., Foley, S. F., and Ware, C. F.
(1993). Lymphotoxin b, a novel member of the TNF family that formsactivities, and its sequence is strongly conserved in or-
a heteromeric complex with lymphotoxin on the cell surface. Cell 72,thopoxvirues and leporipoxviruses, although significantly
847–856.different from that of CrmC. (2) CrmB and CrmC both
Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA
seem to be acquired forms of the cellular TNFRII. The isolation by acid guanidinium thiocyanate-phenol-chloroform extrac-
most likely, though by no means only, explanation may tion. Anal. Biochem. 162, 156–159.
Crouch, A. C., Baxby, D., McCracken, C. M., Gaskell, R. M., and Bennett,reside in the recent discovery that LTa, classically a
AID VY 8100 / 6a1d$$$441 08-08-96 18:02:05 vira AP: Virology
146 SMITH ET AL.
M. (1995). Serological evidence for the reservoir hosts of cowpox J. C. (1993). Potential virulence determinants in terminal regions of
variola smallpox virus genome. Nature 366, 748–751.virus in British wildlife. Epidemiol. Infect. 115, 185–191.
Crowe, P. D., VanArsdale, T. L., Walter, B. N., Ware, C. F., Hession, C., McMahan, C. J., Slack, J. L., Mosley, B., Cosman, D., Lupton, S. D.,
Brunton, L. L., Grubin, C. E., Wignall, J. M., Jenkins, N. A., Brannan,Ehrenfels, B., Browning, J. L., Din, W. S., Goodwin, R. G., and Smith,
C. A. (1994). A lymphotoxin-b-specific receptor. Science 264, 707– C. I., Copeland, N. G., Huebner, K., Croce, C. M., Cannizzarro, L. A.,
Benjamin, D., Dower, S. K., Spriggs, M. K., and Sims, J. E. (1991). A710.
Davison, A. J., and Moss, B. (1989a). Structure of vaccinia virus early novel IL-1 receptor, cloned from B cells by mammalian expression,
is expressed in many cell types. EMBO J. 10, 2821–2832.promoters. J. Mol. Biol. 210, 749–769.
Davison, A. J., and Moss, B. (1989b). Structure of vaccinia virus late Miura, M., Zhu, H., Rotello, R., Hartwieg, E. A., and Yuan, J. (1993).
Induction of apoptosis in fibroblasts by IL-1b-converting enzyme, apromoters. J. Mol. Biol. 210, 771–784.
Enari, M., Hug, H., and Nagata, S. (1995). Involvement of an ICE-like mammalian homolog of the C. elegans cell death gene ced-3. Cell
75, 653–660.protease in Fas-mediated apoptosis. Nature 375, 78–81.
Falkner, F. G., and Moss, B. (1988). Escherichia coli gpt gene provides Mohler, K. M., Torrance, D. S., Smith, C. A., Goodwin, R. G., Stremler,
K. E., Fung, V. P., Madani, H., and Widmer, M. B. (1993). Soluble tumordominant selection for vaccinia virus open reading frame expression
vectors. J. Virol. 62, 1849–1854. necrosis factor (TNF) receptors are effective therapeutic agents in
lethal endotoxemia and function simultaneously as both TNF carriersGearing, D. P., King, J. A., Gough, N. M., and Nicola, N. A. (1989).
Expression cloning of a receptor for human granulocyte-macrophage and TNF antagonists. J. Immunol. 151, 1548–1561.
Naismith, J. H., Devine, T. Q., Brandhuber, B. J., and Sprang, S. R. (1995).colony-stimulating factor. EMBO J. 8, 3667–3676.
Genetics Computer Group (1991). Program Manual for the GCG Pack- Crystallographic evidence for dimerization of unliganded tumor ne-
crosis factor receptor. J. Biol. Chem. 270, 13303–13307.age. 575 Science Drive, Madison, WI 53711.
Goebel, S. J., Johnson, G. P., Perkus, M. E., Davis, S. W., Winslow, Park, L. S., Friend, D., Sassenfeld, H. M., and Urdal, D. L. (1987). Charac-
terization of the human B cell stimulatory factor 1 receptor. J. Exp.J. P., and Paoletti, E. (1990). The complete DNA sequence of vaccinia
virus. Virology 179, 247–266. Med. 166, 476–488.
Patel, D. D., and Pickup, D. J. (1987). Messenger RNAs of a strongly-Goodwin, R. G., Anderson, D., Jerzy, R., Davis, T., Brannan, C. I., Cope-
land, N. G., Jenkins, N. A., and Smith, C. A. (1991). Molecular cloning expressed late gene of cowpox virus contain 5*-terminal poly(A) se-
quences. EMBO J. 6, 3787–3794.and expression of the type 1 and type 2 murine receptors for tumor
necrosis factor. Mol. Cell. Biol. 11, 3020–3026. Pickup, D. J., Ink, B. S., Parsons, B. L., Hu, W., and Joklik, W. K. (1984).
Spontaneous deletions and duplications of sequences in the genomeHopp, T. P., Prickett, K. S., Price, V. L., Liggy, R. T., March, C. J., Cerretti,
D. P., Urdal, D. L., and Conlon, P. J. (1988). A short polypeptide of cowpox virus. Proc. Natl. Acad. Sci. USA 81, 6817–6821.
Pickup, D. J., Ink, B. S., Hu, W., Ray, C. A., and Joklik, W. K. (1986).marker sequence useful for recombinant protein identification and
purification. Biotechnology 6, 1204–1210. Hemorrhage in lesions caused by cowpox virus is induced by a
viral protein that is related to plasma protein inhibitors by serineHoward, S. T., Chan, Y. S., and Smith, G. L. (1991). Vaccinia virus
homologues of the shope fibroma virus inverted terminal repeat pro- proteases. Proc. Natl. Acad. Sci. USA 83, 7698–7702.
Pickup, D. J. (1994). Poxviral modifiers of cytokine responses to infec-teins and a discontinuous ORF related to the tumor necrosis factor
receptor family. Virology 180, 633–647. tion. Infect. Agents Dis. 3, 116–127.
Ray, C. A., Black, R. A., Kronheim, S. R., Greenstreet, T. A., Sleath,Hu, F.-Q., Smith, C. A., and Pickup, D. J. (1994). Cowpox virus contains
two copies of an early gene encoding a soluble secreted form of P. R., Salvesen, G. S., and Pickup, D. J. (1992). Viral inhibition of
inflammation: Cowpox virus encodes an inhibitor of the interleukin-the type II TNF receptor. Virology 204, 343–356.
Ink, B. S., and Pickup, D. J. (1989). Transcription of a poxvirus early 1b converting enzyme. Cell 69, 597–604.
Rohrmann, G., Yuen, L., and Moss, B. (1986). Transcription of vacciniagene is regulated both by a short promoter element and by a tran-
scriptional termination signal controlling transcriptional interference. virus early genes by enzymes isolated from vaccinia virions termi-
nates downstream of a regulatory sequence. Cell 46, 1029–1035.J. Virol. 63, 4632–4644.
Kozak, M. (1987). An analysis of 5*-noncoding sequences from 699 Sambrook, J., Fritsch, E., and Maniatis, T. (1989). ‘‘Molecular Cloning:
A Laboratory Manual,’’ 2nd ed. Cold Spring Harbor Press, Cold Springvertebrate messenger RNAs. Nucleic Acids Res. 15, 8125–8148.
Kyte, J., and Doolittle, R. F. (1982). A simple method for displaying the Harbor, New York.
Schwer, B., Visca, P., Vos, J. C., and Stunnenberg, H. G. (1987). Discon-hydropathic character of a protein. J. Mol. Biol. 157, 105–132.
Laemmli, U. K. (1970). Cleavage of structural proteins during the assem- tinuous transcription or RNA processing of vaccinia virus late mes-
sengers results in a 5* poly(A) leader. Cell 50, 163–169.bly of the head of bacteriophage T4. Nature 227, 680–685.
Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Shchelkunov, S. N., Marennikova, S. S., Blinov, V. M., Resenchuk,
S. M., Tetmenin, A. V., Chizhikov, V. E., Gutorov, V. V., Safronov,Baeuerle, P. A., Droge, W., Krammer, P. H., Fiers, W., and Schulze-
Osthoff, K. (1995). Requirement of an ICE/CED-3 protease for Fas/ P. F., Kurmanov, R. K., and Sandakhchiev, L. S. (1993). Entire coding
sequence of the variola virus. Dokl. Akad. Nauk. 328, 629–632.APO-1-mediated apoptosis. Nature 375, 81–83.
Mackett, M., Smith, G. L., and Moss, B. (1982). Vaccinia virus: A se- Smith, C. A., Davis, T., Anderson, D., Solam, L., Beckmann, M. P., Jerzy,
R., Dower, S. K., Cosman, D., and Goodwin, R. G. (1990). A receptorlectable eukaryotic cloning and expression vector. Proc. Natl. Acad.
Sci. USA 79, 7415–7419. for tumor necrosis factor defines an unusual family of cellular and
viral proteins. Science 248, 1019–1023.Mackett, M., Smith, G. L., and Moss, B. (1984). General method for
production and selection of infectious vaccinia virus recombinants Smith, C. A., Davis, T., Wignall, J. M., Din, W. S., Farrah, T., Upton, C.,
McFadden, G., and Goodwin, R. G. (1991). T2 open reading frameexpressing foreign genes. J. Virol. 49, 857–864.
Marrack, P., and Kappler, J. (1994). Subversion of the immune system from the shope fibroma virus encodes a soluble form of the TNF
receptor. Biochem. Biophys. Res. Commun. 176, 335–342.by pathogens. Cell 76, 323– 332.
Martinez-Pomares, L., Stern, R. J., and Moyer, R. W. (1993). The ps/hr Smith, C. A., Gruss, H.-J., Davis, T., Anderson, D., Farrah, T., Baker, E.,
Sutherland, G. R., Brannan, C. I., Copeland, N. G., Jenkins, N. A.,gene (B5R open reading frame homolog) of rabbitpox virus controls
pock color, is a component of extracellular enveloped virus, and is Grabstein, K. H., Gliniak, B., McAlister, I. B., Fanslow, W., Alderson,
M., Falk, B., Gimpel, S., Gillis, S., Din, W. S., Goodwin, R. G., andsecreted into the medium. J. Virol. 67, 5450–5462.
Massung, R. F., Esposito, J. J., Liu, L., Qi, J., Utterback, T. R., Knight, Armitage, R. J. (1993). CD30 antigen, a marker for Hodgkin’s
lymphoma, is a receptor whose ligand defines an emerging familyJ. C., Aubin, L., Yuran, T. E., Parsons, J. M., Loparev, V. N., Selivanov,
N. A., Cavallaro, K. F., Kerlavage, A. R., Mahy, B. W. J., and Venter, of cytokines with homology to TNF. Cell 73, 1349–1360.
AID VY 8100 / 6a1d$$$441 08-08-96 18:02:05 vira AP: Virology
147CPV GENOME ENCODES SECOND SOLUBLE HOMOLOGUE OF CELLULAR TNF RECEPTORS
Smith, C. A., Farrah, T., and Goodwin, R. G. (1994). The TNF receptor CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable
protease that cleaves the death substrate poly(ADP-ribose) polymer-superfamily of cellular and viral proteins: activation, costimulation,
and death. Cell 76, 959–962. ase. Cell 81, 801–809.
Upton, C., Macen, J. L., Schreiber, M., and McFadden, G. (1991). Myx-Smith, C. A., and Goodwin, R. G. (1995). Tumor necrosis factor receptors
in the poxvirus family: biological and genetic implications. In ‘‘Viro- oma virus expresses a secreted protein with homology to the tumor
necrosis factor receptor gene family that contributes to viral viru-ceptors, Virokines and Related Immune Modulators Encoded by DNA
Viruses’’ (G. McFadden, Ed.), pp. 29–40. R.G. Landes Co., Austin. lence. Virology 184, 370–382.
Upton, C., Mossman, K., and McFadden, G. (1992). Encoding of a homo-Smith, C. A., Goodwin, R. G., and Maliszewski, C. R. (1995). Isolation
of cDNA clones by direct expression in mammalian cells. In ‘‘Gene log of the IFN-g receptor by myxoma virus. Science 258, 1369–1372.
Weaver, R. F., and Weissman, C. (1979). Mapping of RNA by a modifica-Probes 2: A Practical Approach’’ (B. D. Hames, and S. J. Higgins,
Eds.), pp. 103–118. IRL Press, Oxford. tion of the Berk-Sharp procedure: 15S b-globin mRNA precursor and
mature 10S b-globin mRNA have identical map coordinates. NucleicSpriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims,
J. E., Buller, R. M. L., and VanSlyke, J. (1992). Vaccinia and cowpox Acids Res. 7, 1175–1193.
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl,viruses encode a novel secreted interleukin-1-binding protein. Cell
71, 145–152. J. K., Sutherland, G. R., Davis Smith, T., Rauch, C., Smith, C. A., and
Goodwin, R. G. (1995). Identification and characterization of a newSymons, J. A., Alcamı´, A., and Smith, G. L. (1995). Vaccinia virus encodes
a soluble type I interferon receptor of novel structure and broad member of the TNF family that induces apoptosis. Immunity 3, 673–
682.species specificity. Cell 81, 551–560.
Talley, A. K., Dewhurst, S., Perry, S. W., Dollard, S. C., Gummuluru, S., Wold, W. S. M., Tollefson, A. E., and Hermiston, T. W. (1994). Strategies
of immune modulation by adenoviruses. In ‘‘Viroceptors, VirokinesFine, S. M., New, D., Epstein, L. G., Gendelman, H. E., and Gelbard,
H. A. (1995). Tumor necrosis factor alpha-induced apoptosis in hu- and Related Immune Modulators Encoded by DNA Viruses’’
(G. McFadden, Ed.), pp. 147–185. R.G. Landes Co., Austin.man neuronal cells: protection by the antioxidant N-acetylcysteine
and the genes bcl-2 and crmA. Mol. Cell. Biol. 15, 2359–2366. Wright, C. F., and Moss, B. (1987). In vitro synthesis of vaccinia virus
late mRNA containing a 5* poly(A) leader sequence. Proc. Natl. Acad.Tewari, M., Quan, L. T., O’Rourke, K., Desnoyers, S., Zeng, Z., Beidler,
D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995). Yama/ Sci. USA 84, 8883–8887.
AID VY 8100 / 6a1d$$$441 08-08-96 18:02:05 vira AP: Virology
